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ABSTRACT 1 
 2 
Background: Many patients experience difficulties adhering to medication regimes. For 3 
people who forget or get confused about medication, there are products to help them 4 
such as multi-compartment medication devices (MMDs). Some of these, known as 5 
electronic MMDs (eMMDs),  use audible and/or visual signals to prompt the patient when 6 
to take  medication, dispense medications, give instructions to the patient, and contact a 7 
caregiver (mobile internet or text to a carer) as needed.   8 
Aim: To systematically review the literature on the use of eMMDs, to determine what 9 
evidence for their effectiveness is available. 10 
Methods: A comprehensive literature search of 10 databases, plus an internet search 11 
and hand searching was conducted, using the MeSH terms reminder systems/patient 12 
compliance/medication adherence. There were no date restrictions. Inclusion criteria 13 
were patients in any community setting, in any country and with no restrictions of age, 14 
gender, ethnicity or medical condition, using an eMMD.  Peer-reviewed quantitative or 15 
qualitative studies of any design were included.    16 
Results: Of 805 abstracts identified and 99 full text papers retrieved, six met the 17 
inclusion criteria. Five of the studies reported adherence to medication regimes; one 18 
reported design factors to improve adherence. Adherence varied by the context of the 19 
reminders, the target group and usability of the devices. The studies were small scale 20 
and only one was a well conducted randomised controlled trial.     21 
Conclusion: Overall methodological quality of the studies was poor. Although positive 22 
effects on adherence were reported further, rigorously conducted, studies are needed to 23 
inform the use of eMMDs. 24 
 25 
Keywords: Medication device, patient adherence, reminder systems. 26 
 27 
 28 
 29 
 30 
INTRODUCTION 31 
 32 
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15 million UK adults1 are living with chronic disease, 30% of whom have multiple 33 
morbidity requiring polypharmacy, and many have some level of cognitive impairment.  34 
This number is estimated to double by 20302. Medication adherence problems are 35 
common and associated with poor disease control including hospitalisation and death3-8.  36 
There are also other financial implications; it has been estimated that in the UK the cost 37 
of medications unused and returned to pharmacists9 is £100 million per annum. 38 
 39 
Non-adherence may be unintentional or intentional.  Unintentional non-adherence is 40 
usually due to practical problems such as poor instructions, poor memory or cognitive 41 
defects, multiple medications to be taken or difficulty in opening packaging10.  42 
Intentional non-adherence is largely associated with poor motivation and negative beliefs 43 
about medication. While both types of non-adherence can result in failure to take any of 44 
the medicine, the most common form of non-adherence is doses missing because of 45 
forgetfulness, changed medication schedules or busy lifestyles110.  46 
 47 
A review121 of medication adherence identified four general categories to improve 48 
adherence: patient education; improved dosing schedules; increased access to health 49 
care; and improved communication between physicians and patients. Strategies to 50 
improve dosing schedules were described, including the use of pillboxes to organize daily 51 
doses, simplifying the regimen to daily dosing, and cues to remind patients to take 52 
medications.  Another review132 which assessed current research on determinants of 53 
patient adherence found that multifaceted interventions are most likely to improve 54 
adherence. A recent Cochrane review143 of interventions to improve adherence found 55 
that while almost all of the effective interventions were complex these did not lead to 56 
large improvements in adherence and treatment outcomes.  57 
 58 
A Kings Fund report on polypharmacy154 noted that adherence problems increase as 59 
medicine regimens become more complex. It concluded that there is a need to develop 60 
systems that optimise medicines use for patients taking multiple medications, to   61 
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maximise benefit, minimise risk and reduce harm and waste. Solutions proposed 62 
included training programmes, improved electronic decision support for clinicians and/or 63 
patients, patient-friendly information systems, the use of monitored dose systems and 64 
clinical audit.  A report on the use of multi-compartment compliance aids165 (MCAs) 65 
concluded that MCAs may be of value for some patients who have been assessed as 66 
having practical problems in managing their medicines. The ease of use of MCAs has also 67 
been investigated176 as problems with accessing medication from its packaging in a MCA 68 
had been reported by 54% of participants. This suggests that modifications need to be 69 
made and it may be that electronic storage and dispensing methods with reminder 70 
systems could be a useful addition if they are found to increase adherence.  71 
 72 
There are now electronic Medicine Management Devices (eMMDs) that can prompt the 73 
patient when to take a medicine using audible and/or visual signals, dispense medicines 74 
at the appropriate times, give instructions to the patient, and contact a caregiver 75 
(usually by mobile technology) if medicines are not removed or are not taken at the 76 
right time.  Reminders and alerts can be set up by health care professionals or carers. 77 
Such devices are heavily promoted by manufacturers and described in government 78 
policy documents187.  However, it is not known if these electronic devices provide any 79 
advantage over regular MMDs in terms of better adherence to a medication plan.   80 
The aim of this systematic literature review was to determine: if there is evidence that 81 
the use of eMMDs improves adherence; for which patient groups and for which condition 82 
types they are most likely to be successful in improving adherence and health outcomes; 83 
how acceptable are they to users, carers and health care professionals and if there is 84 
evidence of cost savings from their usage. 85 
 86 
METHODS 87 
Inclusion criteria 88 
Studies were included from all community settings and countries and no restrictions 89 
were made in terms of SDWLHQWV¶age, gender, ethnicity, medical condition or types of 90 
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medication. Peer-reviewed qualitative and quantitative studies of all designs were 91 
included.   92 
Studies investigating multi-compartmental devices which met at least one of the 93 
following criteria were included: 94 
1. Prompted the patient when to take a medicine using audible and/or visual signals 95 
and/or dispensed medicines at the appropriate times. 96 
2. Gave instructions to the patient, and/or contacted a caregiver if medicines were 97 
not removed or were taken at the wrong time.  98 
Outcomes 99 
Outcomes to be collected included adherence measures, clinical outcomes, usability, and 100 
satisfaction with the intervention.  101 
 102 
Search methods for identification of studies 103 
The MeSH terms for the database search were reminder systems/ patient compliance/ 104 
medication adherence. See Appendix 1 for detailed search terms. 105 
 106 
The databases of the Cochrane Central Register of Controlled Trials (Trials along with 107 
EED and HTA) and the Database of Abstracts of Reviews of Effects (DARE), MEDLINE, 108 
EMBASE, CINAHL, EBSCO, PsycINFO, Scopus, ASSIA and Web of Science were searched. 109 
Current Controlled Trials was searched to identify trials in progress. The Internet was 110 
searched using the Google academic search engine (http://scholar.google.com) looking 111 
at the first 300 returns on the relevance ranking, electronic reminder system 112 
manufacturers contacted, and abstracts from the Pharm-line database checked. Internet 113 
search terms were based on the MeSH terms for drug administration and drug delivery 114 
systems and reminder systems along with the specific trade names.  Reference lists of 115 
papers retrieved in full text for relevant studies were also searched.  Hand searches of 116 
journals and meetings abstracts were carried out. There were no language restrictions 117 
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applied in the initial search, however full text versions of papers not published in English 118 
were excluded as no translation service was available.  There were no date restrictions.   119 
 120 
Selection of studies 121 
The search strategy (see Appendix 1) was implemented by MP on 26 March 2014 and 122 
references imported to Endnote and duplicates removed.  MP checked all the titles and 123 
abstracts of potentially relevant studies and these were independently checked by at 124 
least one other member of the research team. Full text copies of potentially relevant 125 
studies were obtained and these were assessed by MP and one other member of the 126 
team for their eligibility for inclusion against the criteria outlined above. Disagreements 127 
were resolved by discussion. 128 
   129 
Data extraction and management 130 
The following data were extracted by two independent reviewers (MP and one other 131 
member of the team) from the studies using a customised data extraction form in Excel: 132 
x Country and setting 133 
x Study design 134 
x Participants (sample size, mean age, gender ratio) 135 
x Medical condition/medication 136 
x eMMD system 137 
x Adherence measure  138 
x Other reported outcomes including clinical outcomes,  acceptability, barriers and 139 
facilitators to the use of eMMDs,  the experience and usability of the devices   140 
x Study tools e.g. questionnaire 141 
x Costings 142 
 143 
Quality assessment and reporting biases in included studies 144 
Studies were assessed for the risk of potential bias using the Critical Appraisal Skills 145 
Programme (CASP)198 questions as appropriate to the study design.  For randomised 146 
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controlled trials (RCT) this included allocation procedures, blinding, attrition, power of 147 
study and whether positive results had been stressed over negative results. For a cohort 148 
study this included: the population, subjective or objective measures, accuracy of 149 
outcome measurement to minimise bias, and consideration of confounding factors if they 150 
were identified.  For a qualitative study this included the rigour of data collection, the 151 
type of analysis and clarity of the statement of findings. Using the answers to the 152 
questions as an indication of quality, an overall quality assessment for each study was 153 
determined.  154 
 155 
Summary measures and synthesis of results 156 
Where available, the difference in mean adherence was reported. Otherwise the studies 157 
are reported narratively.  158 
 159 
RESULTS 160 
Study selection  161 
A total of 805 titles/abstracts was identified. After removal of duplicates 749 abstracts 162 
were screened, of which 650 were excluded as they contained no explicit mention of 163 
electronic reminders. Full text articles were obtained for the remaining 99.  Three 164 
articles, identified from citation lists or the grey literature were rejected because they 165 
had not been peer reviewed.  The PRISMA chart is shown in Figure 1.    166 
 167 
Study characteristics 168 
Six articles met the full inclusion criteria and the main characteristics are summarised in 169 
Table 1.  The studies were conducted between 2008 and 2013, in countries in North 170 
America, Europe and Asia.  There was a range of study designs from observational 171 
studies (3), a controlled longitudinal study (1) and RCTs (2). The studies used eMMDs 172 
with different levels of sophistication of electronic reminders but all with alarms that 173 
were triggered by different contextual factors or with the facility to contact users or 174 
carers.  Hayakawa et al.2019 interviewed 116 patients attending (as outpatients) 175 
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cardiovascular or metabolic disease departments to inform the development of an eMMD, 176 
followed by a feasibility study in which 10 patients used the device.  Hayes et al.210 used 177 
adherence to vitamin pills to explore the effectiveness of a complex reminder 178 
intervention in 10 elderly people where forgetfulness was an issue. Lo et al.221 carried 179 
out an ethnographic study observing the use of an eMMD followed by a satisfaction 180 
survey of 30 healthy volunteers to explore the desired properties and the barriers to use 181 
of such a device. Schmidt et al.232 conducted a controlled longitudinal study of 62 182 
patients with high blood pressure and congestive heart failure (CHF) taking 183 
antihypertensive medication to determine if an eMMD could improve adherence.  Simoni 184 
et al.243 used an eMMD combined with cognitive behavioural therapy (CBT) in a RCT with 185 
40 HIV positive patients with depression taking anti-retroviral medication. Stip et al.254 186 
tested an eMMD in a RCT of 47 people with schizophrenia taking anti-psychotic 187 
medications.   188 
 189 
Effects of the intervention on adherence rates 190 
Hayakawa et al. tested the design and feasibility of a smartphone based reminder 191 
system which linked wirelessly to a pillbox and included real-time medication monitoring.  192 
According to the self-reports from 116 interviews 46 (41.1%) patients forgot to take 193 
their medication, or took their medication more than two hours behind schedule, more 194 
than once a week. In the feasibility study of the pillbox with 10 patients, delay in taking 195 
medicine within the scheduled time occurred 47 times out of 127 (37.0%) and in 17 of 196 
the 47 occasions (36.2%) patients took their medication upon being presented with only 197 
one reminder.  198 
 199 
Hayes et al. compared three types of reminder systems in older patients who lived alone 200 
and were considered to be poorly adherent.  They reported that adherence rates varied 201 
with the situation in which prompts were administered. Context-aware prompting which 202 
only occurred when participants had forgotten to take their pills and were in a situation 203 
where they were likely to be able to take their pills, resulted in a mean adherence of 204 
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92.3% (95% CI 84.7-97.0).  Using time based reminders alone adherence was 73.5% 205 
(95% CI 68.0-78.6), and with no prompting 68.1% (95% CI 57.5-80.5). Adherence was 206 
tracked by the eMMD.   207 
 208 
Schmidt et al. studied adherence when using an eMMD in patients with CHF taking 209 
antihypertensive medication who had self-reported or physician reported compliance 210 
problems (n=32). Medication intake data was transferred by the eMMD to an electronic 211 
health record and was monitored by health care professionals.   Compliance was 212 
measured by the number of interventions needed to remind patients to take medication 213 
if they failed to take medication when the alarm went off.  More than 50% of patients 214 
made only 0-2 mistakes during the 2 month period although this varied greatly with one 215 
patient needing 19 interventions.   216 
 217 
Simoni et al. conducted a RCT to examine the efficacy of a CBT intervention for 218 
depression used simultaneously with an eMMD (Medsignals®), compared to an identical 219 
pillbox with the alert system deactivated and with no CBT, in patients with HIV receiving 220 
antiretroviral therapy who were sub-optimally adherent.  Adherence was monitored by 221 
self-reports using a visual analogue scale265 and an embedded log in the pillbox that 222 
recorded compartment openings and uploaded the data to a web based system. They 223 
reported that greater adherence was recorded by the intervention group using the eMMD 224 
with an odds ratio of 3.78 (SE=1.31, 95% CI=1.62-7.26, p=0.001).  Similar findings 225 
were reported for the self-reports (OR=3.34, SE=1.31, 95% CI=1.62-7.26, p=0.001).  226 
 227 
Stip et al. conducted a RCT to test if an eMMD (DoPill®) with an alarm and real time 228 
information improved adherence in schizophrenic patients taking anti-psychotic 229 
medications compared with a control group using a Medication Events Monitoring System 230 
(MEMS®) device which only recorded openings. The use of the eMMD showed a mean 231 
antipsychotic adherence rate (AAR) (number of pills taken / number of pills prescribed X 232 
100) of 67% which was comparable for both devices.  The raw results indicated that 233 
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more adherent patients at baseline evidenced greater improvement in adherence relative 234 
to more non-adherent patients, with ARRs of 98-100% when using the eMMD.  This 235 
suggests there may be a limit to the benefit that electronic aids can have for increasing 236 
adherence in those who are not simply forgetful.  Adherence was also measured by the 237 
Brief Adherence Rating Scale (BARS) ratio, a self-report and clinician assessment of 238 
adherence which is used to assess medication adherence in schizophrenia and was 239 
reported in the literature276 to show an AAR of about 49.5% in the general schizophrenic 240 
population.   The AAR measured by BARS in this study was found to be 86-99% 241 
suggesting that BARS was not an accurate indicator of adherence in this group of 242 
participants.   243 
 244 
Effects of the intervention on health outcomes  245 
Simoni et al. reported improved biological markers of cell counts for HIV viral load for 246 
patients taking antiretroviral drugs and psychological indicators of depressive symptoms 247 
using the Beck Depressive Inventory-1A (BDI-IA) and the Montgomery-Åsberg 248 
Depression Rating Scale (MADRS). The primary depressive symptoms outcomes were 249 
assessed with a self-report on the BDI-IA and a semi-structured interview by an 250 
independent rater blind to treatment condition using the MADRS.  Intervention 251 
participants demonstrated a greater drop in depressive scores in BDI-IA scores (OR = -252 
3.64, SE=1.78, 95% CI=-7.26 to 0.01, p = 0.05) and to a lesser extent MADRS scores 253 
(OR=-5.14, p=0.14).  Biological markers indicated some relative improvement for CD4 254 
cell count (OR = 69.45, SE = 38.57, 95 % CI = -6.16 to 145.05, p = 0.07), but not for 255 
viral load (OR=0.14, 95%CI=-0.75-1.03, p=0.75).  256 
 257 
Schmidt et al. compared the intervention group with a control group of CHF patients 258 
(n=30) who did not have adherence problems, did not use the eMMD and had better 259 
mental and physical health at baseline.  They found a significant improvement in mental 260 
health in the intervention group based on self-reported health status in the 12-Item 261 
Short Form Health Survey27 (T= -3.09, p0.01) from baseline to the 2 month 262 
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assessment.  The mental health of the control group did not change significantly 263 
(T=1.81, p=0.05) in this time. 264 
 265 
Usability issues 266 
Lo et al. found an eMMD could enhance adherence if it could be used flexibly in different 267 
contexts, was not too large, the alarm was not so intrusive that it overcame privacy if 268 
used outside the home and interface complexity was reduced to simplify the operating 269 
system. Older adults in the feasibility study of 30 patients (15 > 65 years, 15 < 65 270 
years) preferred a pillbox that integrated both pillbox and reminder functions rather than 271 
using a separate mobile phone as the reminder.  Hayakawa et al. found 51 out of 112 272 
(45.5%) took their medications outside the home more than once a week, suggesting 273 
that portable pillboxes may support medication self-management.  Schmidt et al. found 274 
the features with the most potential for improvement were more flexible programme 275 
timing and mobile solutions for the pillbox. Hayes et al. identified benefits for the elderly 276 
in not being required to carry medication dispensers but rather having a system that 277 
monitors their movements to determine when medication prompting should be carried 278 
out.  279 
 280 
Limitations of the studies 281 
All the studies included in the review had methodological problems.  They were limited 282 
by small numbers, inadequate control groups and often included complex interventions 283 
of which adherence technology was only a part.  The limitations are summarised in Table 284 
2.  The CASP quality assessment tools were used to determine the quality but due to the 285 
mixed methods used by the studies a full comparison was not meaningful. A cost 286 
analysis was not reported in any of the included studies. 287 
 288 
DISCUSSION  289 
This review suggests eMMDs may improve adherence.  However all the studies had 290 
methodological limitations, and larger, well conducted controlled trials, with longer term 291 
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outcomes are required to confirm this.  SStudies using anof eMMDs as use the 292 
technology as both the intervention and the tool to measure adherence,  the intervention 293 
cannot separate the adherence measurement tool  which may introduces  bias. making it 294 
difficult to assess the sole effect of the eMMD which may also partly explain the low 295 
effect found.  Most Furthermore most of the studies in this review were at the feasibility 296 
stage and did not report in detail on clinical outcomes.  The elderly with cognitive 297 
problems and patients with conditions where timing and adherence to medication 298 
regimes are critical were the groups most likely to benefit from these more sophisticated 299 
reminder devices. The usability, mobility of the device and the flexibility of timing of 300 
reminders were identified as issues that still need to be addressed.  301 
 302 
Previous reviews in this area have focused on electronic reminders but not particularly 303 
on eMMDs. A review by Fenerty 298 found no significant difference in adherence rate for 304 
patient reported results compared to electronic monitoring systems. It was unclear 305 
whether one type of reminder system had a significant impact on adherence.  The review 306 
concluded that the type of medication could influence the adherence rate and that 307 
chronic and asymptomatic illnesses may be most resistant to adherence-enhancing 308 
strategies. Similarly Vervolet 3029 reviewed studies using electronic reminders but only 309 
one of the papers in this review concerned an eMMD and this was included in our review. 310 
The review provided evidence for the short term effectiveness of electronic reminders 311 
but the effects in the long term were unclear. 312 
 313 
This review showed that electronic reminders combined with MMDs may have the 314 
potential to lead to improvements in SDWLHQWV¶DGKHUHQFHWRPHGLFDWLRQEXWWKHFRQWH[W315 
usability and medical condition influence their usefulness. Further high quality studies in 316 
a range of contexts are required to establish if the use of eMMDs as a long term aid or 317 
possibly as an interim tool to achieve adherence is effective and cost-effective. 318 
 319 
 320 
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